Filing Details
- Accession Number:
- 0001179110-12-015072
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-10-10 20:00:10
- Reporting Period:
- 2012-10-10
- Filing Date:
- 2012-10-10
- Accepted Time:
- 2012-10-10 19:00:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1282660 | R Julianna Wood | C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080 | Vp, Public Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-10-10 | 1,532 | $30.28 | 19,751 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2012-10-10 | 1,321 | $28.55 | 21,072 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-10-10 | 2,853 | $86.95 | 18,219 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-10-10 | 1,532 | $0.00 | 1,532 | $30.28 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2012-10-10 | 1,321 | $0.00 | 1,321 | $28.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
9,187 | 2020-03-31 | No | 4 | M | Direct | |
4,240 | 2019-03-31 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 200 | Indirect | Children's Trust |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.